Noticias de SCYX_US

Noticias del mercado

Últimas noticias sobre SCYX_US — 175 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: SCYX_US ✕ 175 resultados
01/04/2026 SCYX_US — Minichart
SCYNEXIS Acquires PXL-770 (SCY-770) to Advance Innovative ADPKD Therapy with Phase 2 Trial Planned for 2026
01/04/2026 SCYX_US — The Globe and Mail
SCYNEXIS Raises $40 Million in Strategic Private Placement
01/04/2026 SCYX_US — Seeking Alpha
SCYNEXIS, Inc. (SCYX) Discusses Transformative Asset Acquisition and Strategic Shift Toward ADPKD Therapeutics - Slideshow (NASDAQ:SCYX) 2026-04-01
31/03/2026 SCYX_US — Weekly Voice
Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million
31/03/2026 SCYX_US — Stock Titan
Scynexis (NASDAQ: SCYX) buys SCY-770 kidney drug for $8M upfront
31/03/2026 SCYX_US — Stock Titan
SCYNEXIS (SCYX) extends cash runway to 2029 with $40M PIPE and SCY-770 ADPKD deal
31/03/2026 SCYX_US — Stock Titan
Scynexis (NASDAQ: SCYX) prices $40M equity private placement with warrants
31/03/2026 SCYX_US — Stock Titan
Kidney disease drug with Phase 2 study due this year joins SCYNEXIS
31/03/2026 SCYX_US — Stock Titan
SCYNEXIS lands cash to fund rare disease drug work into mid-2029
31/03/2026 SCYX_US — TradingView
Scynexis Acquires Poxel's AMPK Activator Program, Paying $8M Upfront Plus Up To $188M Milestones
31/03/2026 SCYX_US — Contract Pharma
Poxel Sells Kidney‑Disease Drug Candidate to Scynexis for Up to $196 Million
31/03/2026 SCYX_US — Investing.com
SCYNEXIS acquires SCY-770 for rare kidney disease treatment
31/03/2026 SCYX_US — Investing.com
SCYNEXIS raises $40 million in private placement financing
31/03/2026 SCYX_US — TipRanks
SCYNEXIS Acquires SCY-770, Refocuses on Rare Kidney Disease
31/03/2026 SCYX_US — Stocktwits
Scynexis In Spotlight After Poxel Deal, $40 Million Private Placement – SCYX Stock Climbs 2% Pre-Market
31/03/2026 SCYX_US — TipRanks
SCYNEXIS Raises $40 Million in Strategic Private Placement
31/03/2026 SCYX_US — The Manila Times
SCYNEXIS Announces $40.0 Million Private Placement
31/03/2026 SCYX_US — The Manila Times
SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
31/03/2026 SCYX_US — Investing.com South Africa
SCYNEXIS acquires SCY-770 for rare kidney disease treatment By Investing.com
31/03/2026 SCYX_US — Yahoo Finance
Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million

Página 8 de 9

keyboard_arrow_up